

## 12-4079: Phospho-NDRG1 (Thr346) (Clone: F5) rabbit mAb

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	NDRG1T346-F5
<b>Application :</b>	FACS,WB
<b>Reactivity :</b>	Human, Mouse
<b>Conjugate :</b>	Unconjugated
<b>Format :</b>	Purified
<b>Alternative Name :</b>	Differentiation-related gene 1 protein, N-myc downstream-regulated gene 1 protein, Nickel-specific induction protein Cap43, Reducing agents and tunicamycin-responsive protein, RTP, Rit42
<b>Isotype :</b>	Rabbit IgG1k
<b>Immunogen Information :</b>	A synthetic phospho-peptide corresponding to residues surrounding Thr346 of human phospho NDRG1

### Description

N-Myc down-regulated gene 1 (NDRG1) has been reported to be a direct transcriptional target of p53. NDRG1 appears to play a necessary, but not sufficient, role in apoptosis, though its exact mechanism of action remains unknown. NDRG1 expression is elevated in non-small cell lung cancer cells, promoting cancer growth and reducing cytotoxicity to certain anti-cancer drugs. NDRG1 is also elevated in solid tumors and is recognized as a negative prognostic indicator in breast cancer. Elevated NDRG1 expression is correlated with disease recurrence and metastasis in breast cancer. NDRG1 is phosphorylated by Sgk1, which itself is activated by mTORC2. Phosphorylation of NDRG1 at Thr346 promotes cellular differentiation in adipocytes.

### Product Info

<b>Amount :</b>	20 µl / 200 µl
<b>Content :</b>	1X PBS, 0.02% NaN <sub>3</sub> , 50% Glycerol, 0.1% BSA
<b>Storage condition :</b>	Store at -20°C. Avoid repeated freeze and thaw cycles.

### Application Note

1 µg/mL - 0.001 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.(0.5mg/ml)




Fig-1: Flow cytometric analysis of THP1 cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN $\alpha$  + IL-4 + pervanadate (green) using Phospho-NDRG1 (Thr346) antibody NDRG1T346-F5 at 0.05 µg/mL.




Fig 2 : Peptide blocking flow cytometric analysis of THP1 cells secondary antibody only negative control (light blue) or untreated (orange) using isotype control antibody or untreated (red) or with IFN $\alpha$  + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-NDRG1 (Thr346) antibody NDRG1T346-F5 at 0.05  $\mu$ g/mL.




Fig-3: Western blot analysis of C2C12 cell extract untreated or treated with LY294002 using 0.05  $\mu$ g/mL Phospho-NDRG1 (Thr346) antibody NDRG1T346-F5




Fig-4: Western blot analysis of C2C12 cell extract untreated or treated with LY294002 using 0.05  $\mu$ g/mL Phospho-NDRG1 (Thr346) antibody NDRG1T346-F5 or Company C antibody at 0.07  $\mu$ g/mL (manufacturer's recommended concentration) developed using the same exposure.